Advances in Disease-Modifying Therapy of Neuromyelitis Optic Spectrum Disorders

ZHANG Xuanling,CHEN Chaoyang,WEI Ran,ZHOU Ying

DOI: https://doi.org/10.12376/j.issn.2097-0501.2024.02.015

2024-01-01

Abstract:Neuromyelitis optic spectrum disorders(NMOSD)is a serious inflammatory demyelinating disease.Clinical treatment of NMOSD mainly involves acute phase treatment and remission phase prevention treatment.Disease-modifying therapy(DMT)in remission phase of NMOSD can effectively reduce disease re-currence and delay disability progression.At present,the drugs commonly used for DMT at home and abroad in-clude classical immunosuppression,B-cell surface antigen monoclonal antibody,complement targeting mono-clonal antibody,IL-6 receptor-targeting monoclonal antibody,etc.This paper mainly reviews the DMT drugs ef-ficacy,safety,as well as the marketing status of NMOSD.